Tau Immunotherapy Modulates Both Pathological Tau and Upstream Amyloid Pathology in an Alzheimer's Disease Mouse Model

In Alzheimer's disease (AD), the pathological accumulation of tau appears to be a downstream effect of amyloid β protein (Aβ). However, the relationship between these two proteins and memory loss is unclear. In this study, we evaluated the specific removal of pathological tau oligomers in aged Tg2576 mice by passive immunotherapy using tau oligomer-specific monoclonal antibody. Removal of tau oligomers reversed memory deficits and accelerated plaque deposition in the brain. Surprisingly, Aβ*56 levels decreased, suggesting a link between tau and Aβ oligomers in the promotion of cognitive decline. The results suggest that tau oligomerization is not only a consequence of Aβ pathology but also a critical mediator of the toxic effects observed afterward in AD. Overall, these findings support the potential of tau oligomers as a therapeutic target for AD.

[1]  D. Quartermain,et al.  Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model , 2010, The Journal of Neuroscience.

[2]  D. Selkoe,et al.  Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration , 2011, Proceedings of the National Academy of Sciences.

[3]  M. Vitek,et al.  Tau is essential to beta -amyloid-induced neurotoxicity. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[5]  S. Lesné.  Breaking the Code of Amyloid-β Oligomers , 2013, International journal of cell biology.

[6]  Mikio Shoji,et al.  Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.

[7]  K. Ashe,et al.  Cognitive effects of cell-derived and synthetically derived Aβ oligomers , 2011, Neurobiology of Aging.

[8]  R. Kayed,et al.  Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target? , 2013, ImmunoTargets and therapy.

[9]  U. Sengupta,et al.  Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau , 2012, Scientific Reports.

[10]  K. Ashe,et al.  Tau Mislocalization to Dendritic Spines Mediates Synaptic Dysfunction Independently of Neurodegeneration , 2010, Neuron.

[11]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[12]  L. Mucke,et al.  Fyn Kinase Modulates Synaptotoxicity, But Not Aberrant Sprouting, in Human Amyloid Precursor Protein Transgenic Mice , 2004, The Journal of Neuroscience.

[13]  Phillip B. Jones,et al.  Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. , 2007, The American journal of pathology.

[14]  Michela Gallagher,et al.  A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.

[15]  Dominic Holland,et al.  Amyloid‐β associated volume loss occurs only in the presence of phospho‐tau , 2011, Annals of neurology.

[16]  R. Kayed.  Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease , 2010, Human vaccines.

[17]  E. Mandelkow,et al.  Aβ Oligomers Cause Localized Ca2+ Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines , 2010, The Journal of Neuroscience.

[18]  B. Yankner,et al.  β-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding , 1995, Neuron.

[19]  P. T. Nguyen,et al.  Dendritic Spine Abnormalities in Amyloid Precursor Protein Transgenic Mice Demonstrated by Gene Transfer and Intravital Multiphoton Microscopy , 2005, The Journal of Neuroscience.

[20]  R. Nitsch,et al.  β-Amyloid Induces Paired Helical Filament-like Tau Filaments in Tissue Culture* , 2003, Journal of Biological Chemistry.

[21]  J. Sweatt,et al.  Loss of α7 Nicotinic Receptors Enhances β-Amyloid Oligomer Accumulation, Exacerbating Early-Stage Cognitive Decline and Septohippocampal Pathology in a Mouse Model of Alzheimer's Disease , 2010, The Journal of Neuroscience.

[22]  H. Vinters,et al.  AD synapses contain abundant Aβ monomer and multiple soluble oligomers, including a 56-kDa assembly , 2012, Neurobiology of Aging.

[23]  M. Vitek,et al.  Tau is essential to β-amyloid-induced neurotoxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Hardy,et al.  Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.

[25]  K. Zahs,et al.  Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults. , 2013, JAMA neurology.

[26]  U. Sengupta,et al.  Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice , 2011, Molecular Neurodegeneration.

[27]  J. Hardy,et al.  A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. , 2000, Nature.

[28]  Brian J. Wiltgen,et al.  Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-b , 2012 .

[29]  E. Bigio,et al.  Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. , 2008, Neurobiology of aging.

[30]  D. Borchelt,et al.  Environmental Enrichment Exacerbates Amyloid Plaque Formation in a Transgenic Mouse Model of Alzheimer Disease , 2003, Journal of neuropathology and experimental neurology.

[31]  Hans-Ulrich Demuth,et al.  Prion-Like Behavior and Tau-dependent Cytotoxicity of Pyroglutamylated β-Amyloid , 2012, Nature.

[32]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[33]  L. Buée,et al.  Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. , 2012, Current Alzheimer research.

[34]  Kimberly Scearce-Levie,et al.  Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. , 2007, The Journal of biological chemistry.

[35]  G. Bloom.  Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. , 2014, JAMA neurology.

[36]  Frank M LaFerla,et al.  A novel BACE1-regulating protein with therapeutic potential , 2012, Alzheimer's & Dementia.

[37]  U. Sengupta,et al.  Identification of oligomers at early stages of tau aggregation in Alzheimer's disease , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  Y. Shitaka,et al.  Exclusive association and simultaneous appearance of congophilic plaques and AT8-positive dystrophic neurites in Tg2576 mice suggest a mechanism of senile plaque formation and progression of neuritic dystrophy in Alzheimer’s disease , 2004, Acta Neuropathologica.

[39]  B. Hyman,et al.  Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function , 2005, Science.

[40]  J. Sweatt,et al.  Accelerated Plaque Accumulation, Associative Learning Deficits, and Up-regulation of α7 Nicotinic Receptor Protein in Transgenic Mice Co-expressing Mutant Human Presenilin 1 and Amyloid Precursor Proteins* , 2002, The Journal of Biological Chemistry.

[41]  L. Mucke,et al.  Fyn Kinase Induces Synaptic and Cognitive Impairments in a Transgenic Mouse Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[42]  D. Bennett,et al.  The Complex PrPc-Fyn Couples Human Oligomeric Aβ with Pathological Tau Changes in Alzheimer's Disease , 2012, The Journal of Neuroscience.

[43]  K. Ashe.  Molecular basis of memory loss in the Tg2576 mouse model of Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[44]  E. Bigio,et al.  Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers , 2008, Neurobiology of Aging.

[45]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[46]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[47]  L. Mucke,et al.  Accelerating Amyloid-β Fibrillization Reduces Oligomer Levels and Functional Deficits in Alzheimer Disease Mouse Models* , 2007, Journal of Biological Chemistry.

[48]  U. Sengupta,et al.  Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles , 2014, The Journal of Neuroscience.

[49]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[50]  F. LaFerla,et al.  Systemic vaccination with anti‐oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg‐AD mice , 2013, Journal of neurochemistry.

[51]  D. Wilcock,et al.  Passive Amyloid Immunotherapy Clears Amyloid and Transiently Activates Microglia in a Transgenic Mouse Model of Amyloid Deposition , 2004, The Journal of Neuroscience.

[52]  Mark Bowlby,et al.  Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[53]  G. Jackson,et al.  Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies. , 2011, Current Alzheimer research.

[54]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[55]  F. van Leuven,et al.  Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy , 2013, PloS one.

[56]  B. Hyman,et al.  Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.

[57]  F. LaFerla,et al.  p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice , 2014, Neuroscience Letters.

[58]  D. Holtzman,et al.  Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo , 2013, Neuron.

[59]  E. Kandel,et al.  Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice. , 1992, Science.

[60]  D. Karussis,et al.  Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation , 2013, Experimental Neurology.

[61]  U. Sengupta,et al.  Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. , 2014, Journal of Alzheimer's disease : JAD.

[62]  F. LaFerla,et al.  Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease , 2003, Neurobiology of Aging.

[63]  D. Borchelt,et al.  Environmental Enrichment Mitigates Cognitive Deficits in a Mouse Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[64]  K. Ashe,et al.  Plaque-bearing mice with reduced levels of oligomeric amyloid-β assemblies have intact memory function , 2008, Neuroscience.

[65]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[66]  R. Kayed,et al.  Tau aggregates as immunotherapeutic targets. , 2013, Frontiers in bioscience.

[67]  N. Grigoriadis,et al.  Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice , 2010, Experimental Neurology.

[68]  J. Cirrito,et al.  Genetic Modulation of Soluble Aβ Rescues Cognitive and Synaptic Impairment in a Mouse Model of Alzheimer's Disease , 2014, The Journal of Neuroscience.

[69]  Scott A. Small,et al.  Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis , 2008, Neuron.

[70]  P. Davies,et al.  Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity , 2013, PloS one.

[71]  R. Kayed,et al.  Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis , 2006, Neurology.

[72]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[73]  P. Coleman,et al.  Synaptic slaughter in Alzheimer’s disease , 2003, Neurobiology of Aging.

[74]  F. LaFerla,et al.  Reduction of Soluble Aβ and Tau, but Not Soluble Aβ Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles* , 2006, Journal of Biological Chemistry.

[75]  P. Hof,et al.  Changes in dendritic complexity and spine morphology in transgenic mice expressing human wild-type tau , 2010, Brain Structure and Function.

[76]  M. Staufenbiel,et al.  Changes in Amyloid-β and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein , 2013, Science Translational Medicine.

[77]  B. Hyman,et al.  Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease , 2012, Neurobiology of Disease.

[78]  A. Ittner,et al.  Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice , 2011, PloS one.

[79]  S. Younkin,et al.  The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. , 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[80]  R. Kayed,et al.  Preparation and characterization of neurotoxic tau oligomers. , 2010, Biochemistry.

[81]  R. Kayed,et al.  A fibril-specific, conformation-dependent antibody recognizes a subset of Aβ plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain , 2009, Acta Neuropathologica.

[82]  S. Younkin,et al.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[83]  E. Mandelkow,et al.  Linking Amyloid-β and Tau: Amyloid-β Induced Synaptic Dysfunction via Local Wreckage of the Neuronal Cytoskeleton , 2011, Neurodegenerative Diseases.

[84]  R. Huganir,et al.  Tau phosphorylation and tau mislocalization mediate soluble Aβ oligomer‐induced AMPA glutamate receptor signaling deficits , 2014, The European journal of neuroscience.

[85]  George A. Carlson,et al.  The Relationship between Aβ and Memory in the Tg2576 Mouse Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.

[86]  Elizabeth Head,et al.  Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers , 2007, Molecular Neurodegeneration.

[87]  P. Davies,et al.  Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models , 2011, The Journal of Biological Chemistry.